VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

T. gondii DNA vaccine pSAG1-ROP2-SAG2
Vaccine Information
  • Vaccine Name: T. gondii DNA vaccine pSAG1-ROP2-SAG2
  • Target Pathogen: Toxoplasma gondii
  • Target Disease: Toxoplasmosis
  • Vaccine Ontology ID: VO_0004312
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • p30 gene engineering:
    • Type: DNA vaccine construction
    • Description: Vector pcDNA3·1 (–) expressed SAG1-ROP2 and SAG2 gene fragments (Cui et al., 2008).
    • Detailed Gene Information: Click Here.
  • SAG2 gene engineering:
    • Type: DNA vaccine construction
    • Description: Vector pcDNA3·1 (–) expressed SAG1-ROP2 and SAG2 gene fragments (Cui et al., 2008).
    • Detailed Gene Information: Click Here.
  • ROP2 gene engineering:
    • Type: DNA vaccine construction
    • Description: Vector pcDNA3·1 (–) expressed SAG1-ROP2 and SAG2 gene fragments (Cui et al., 2008).
    • Detailed Gene Information: Click Here.
  • DNA vaccine plasmid:
    • DNA vaccine plasmid name:
    • DNA vaccine plasmid VO ID: VO_0000158
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Mouse Response

  • Vaccination Protocol: Six groups (14 per group) of mice were injected intramuscularly (50 µL in each thigh skeletal muscle) with 100 µg of plasmid DNA suspended in 100 µL sterile PBS. Group I was injected with PBS as control, group II with pcDNA3·1 vector alone as control, group III with pSAG2, group IV with pSAG1-ROP2, group V with pSAG1-ROP2-SAG2 and group VI with pSAG1-ROP2-SAG2 + pIL-12 (100 µg each). The mice were immunized on days 0, 14 and 28 with the same protocol. (Cui et al., 2008)
  • Vaccine Immune Response Type: VO_0000286
  • Challenge Protocol: On day 56, seven immunized mice per group were challenged with 10^4 tachyzoites of the T. gondii RH strain. The survival days of the mice was recorded. (Cui et al., 2008)
  • Efficacy: Higher survival rates after lethal challenge were obtained in mice immunized with pSAG1-ROP2-SAG2 as compared to the mice immunized with PBS, expression vector alone or pSAG2, or pSAG1-ROP2. In addition, the protection induced by pSAG1-ROP2-SAG2 was remarkably enhanced by pIL-12 co-administration (Cui et al., 2008).
References
Cui et al., 2008: Cui YL, He SY, Xue MF, Zhang J, Wang HX, Yao Y. Protective effect of a multiantigenic DNA vaccine against Toxoplasma gondii with co-delivery of IL-12 in mice. Parasite immunology. 2008; 30(5); 309-313. [PubMed: 18331395].